A Phase IV, Randomized, Multi-Center, Open-Label, Prospective, Crossover Study to Evaluate Patient Preference of Movantik™ Versus Polyethylene Glycol 3350 for Opioid-Induced Constipation (OIC) Treatment

Trial Profile

A Phase IV, Randomized, Multi-Center, Open-Label, Prospective, Crossover Study to Evaluate Patient Preference of Movantik™ Versus Polyethylene Glycol 3350 for Opioid-Induced Constipation (OIC) Treatment

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Naloxegol (Primary) ; PEG 3350 (Primary)
  • Indications Constipation
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Sep 2017 Status changed from recruiting to completed.
    • 26 Jul 2017 Planned End Date changed from 22 Jan 2018 to 29 Aug 2018.
    • 26 Jul 2017 Planned primary completion date changed from 22 Jan 2018 to 29 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top